Pharma Focus Asia

FUJIFILM Diosynth Biotechnologies Invests US$55 million for Gene Therapy Facility Expansion

Introduction:

FUJIFILM Diosynth Biotechnologies (FDB) has announced an investment of US$55million to establish a new Gene Therapy Innovation Center.

Features:

The new facility will be adjacent to FDB's existing cGMP gene therapy manufacturing facility in College Station, TX.

The innovation center will have a dedicated process and analytical development laboratories.

The 60,000 square feet laboratories will house state-of-the-art upstream, downstream, and analytical development technologies.

Fujifilm also announced that the additional investments in the project will expand FDB's gene therapy cGMP capacity, with new clean rooms and eight new single-use bioreactors with a capacity of 500 liters to 2,000 liters.

Moreover, the site has been providing gene therapy fill/finish services for both clinical and commercial products since early 2019.

The first stage of the manufacturing expansion is expected to be completed and will start its operations in the fall of 2021.

Specifications:

NameFUJIFILM Diosynth Biotechnologies
TypeExpansion
BudgetUS$55 million
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference